MedTrace Logo

Study to Investigate the Safety Profile of AZD4721 After Single Doses at Different Dose Levels

NCT01889160 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2015-06-25

No results posted yet for this study

Summary

Study to investigate the safety profile of AZD4721 after single doses at different dose levels

Conditions

  • Safety,Plasma AUC and Cmax, Plasma AUC 0-t, t1/2λz, and Tmax

Interventions

DRUG

AZD4721 Solution

1-9 mg/mL liquid solution

DRUG

AZD4721 Placebo

Liquid solution

DRUG

AZD4721 Suspension

9 mg/g liquid suspension

Sponsors & Collaborators

Principal Investigators

  • James Ritter, MD · Quintiles London UK

  • Bengt Larsson, MD · Astrazeneca Molndal, Sweden

  • Stuart Oliver, MD · Astrazeneca UK

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-07-31
Primary Completion
2013-12-31
Completion
2013-12-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01889160 on ClinicalTrials.gov